192 related articles for article (PubMed ID: 25313207)
1. Effect of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis and coexisting nontuberculous mycobacterial infection.
Moon SM; Park HY; Jeong BH; Jeon K; Lee SY; Koh WJ
Antimicrob Agents Chemother; 2015 Jan; 59(1):663-5. PubMed ID: 25313207
[TBL] [Abstract][Full Text] [Related]
2. Effect of a 150 mg dose of rifabutin on serum itraconazole levels in patients with coexisting chronic pulmonary aspergillosis and Mycobacterium avium complex lung disease.
Moon SM; Jhun BW; Lee H; Park HY; Jeon K; Lee SY; Koh WJ
J Infect Chemother; 2017 Sep; 23(9):658-660. PubMed ID: 28284662
[TBL] [Abstract][Full Text] [Related]
3. Rifampin-resistant Mycobacterium kansasii infection in a patient with AIDS who was receiving rifabutin.
Meynard JL; Lalande V; Meyohas MC; Petit JC; Frottier J
Clin Infect Dis; 1997 Jun; 24(6):1262-3. PubMed ID: 9195097
[No Abstract] [Full Text] [Related]
4. Update on rifampin, rifabutin, and rifapentine drug interactions.
Baciewicz AM; Chrisman CR; Finch CK; Self TH
Curr Med Res Opin; 2013 Jan; 29(1):1-12. PubMed ID: 23136913
[TBL] [Abstract][Full Text] [Related]
5. Hyperpigmentation in a patient with AIDS, receiving rifabutin for disseminated Mycobacterium genavense infection.
Figueras C; Garcia L; Bertran JM
Eur J Pediatr; 1998 Jul; 157(7):612. PubMed ID: 9686833
[No Abstract] [Full Text] [Related]
6. Pulmonary Mycobacterium parascrofulaceum Infection in a Patient with Chronic Progressive Pulmonary Aspergillosis: A Case Report and Literature Review.
Ikegami H; Yamasaki K; Kawanami T; Fukuda K; Akata K; Nakamura M; Ikushima I; Fukuda Y; Noguchi S; Yatera K
Intern Med; 2020 Jun; 59(11):1417-1422. PubMed ID: 31866624
[TBL] [Abstract][Full Text] [Related]
7. Tremor: a newly described adverse event with long-term itraconazole therapy.
Lestner JM; Denning DW
J Neurol Neurosurg Psychiatry; 2010 Mar; 81(3):327-9. PubMed ID: 20185472
[TBL] [Abstract][Full Text] [Related]
8. Non-tuberculous mycobacterial lung infection complicated by chronic necrotising pulmonary aspergillosis.
Hafeez I; Muers MF; Murphy SA; Evans EG; Barton RC; McWhinney P
Thorax; 2000 Aug; 55(8):717-9. PubMed ID: 10899252
[TBL] [Abstract][Full Text] [Related]
9. Concomitant use of voriconazole and rifabutin in a patient with multiple infections.
Schwiesow JN; Iseman MD; Peloquin CA
Pharmacotherapy; 2008 Aug; 28(8):1076-80. PubMed ID: 18657024
[TBL] [Abstract][Full Text] [Related]
10. Nontuberculous mycobacterial pulmonary disease and
Geurts K; Zweijpfenning SMH; Pennings LJ; Schildkraut JA; Boeree MJ; Magis-Escurra C; van der Lee H; Verweij PE; Hoefsloot W; van Ingen J
Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 30956203
[No Abstract] [Full Text] [Related]
11. Treatment of thrush with itraconazole solution: evidence for topical effect.
Mascareñas CA; Hardin TC; Pennick GJ; Rinaldi MG; Graybill JR
Clin Infect Dis; 1998 May; 26(5):1242-3. PubMed ID: 9597271
[No Abstract] [Full Text] [Related]
12. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.
Li J; Munsiff SS; Driver CR; Sackoff J
Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767
[TBL] [Abstract][Full Text] [Related]
13. Rapid improvement of osseous sarcoidosis after the treatment of pulmonary aspergillosis by itraconazole.
Murakami K; Tamada T; Abe K; Nara M; Hisata S; Mitsuishi Y; Muramatsu S; Gomi K; Ebina M; Nukiwa T
Sarcoidosis Vasc Diffuse Lung Dis; 2011 Jul; 28(1):75-8. PubMed ID: 21796895
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary infection due to Acrophialophora fusispora in a patient with underlying mixed connective tissue disease and chronic pulmonary aspergillosis: A case report and review of literature.
Samaddar A; Sharma A; Shrimali T
J Mycol Med; 2020 Jun; 30(2):100932. PubMed ID: 32008965
[TBL] [Abstract][Full Text] [Related]
15. Successful Anticoagulation With Warfarin After Switching From Rifampin to Rifabutin.
Alnewais ME; Landolfa SL; Bean M; Fermo JD
J Prim Care Community Health; 2023; 14():21501319231197588. PubMed ID: 37750044
[TBL] [Abstract][Full Text] [Related]
16. [Rifabutin--a new antituberculous antibiotic].
Antibiot Khimioter; 1997; 42(5):47-8. PubMed ID: 9254590
[No Abstract] [Full Text] [Related]
17. Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis.
Jhun BW; Jeon K; Eom JS; Lee JH; Suh GY; Kwon OJ; Koh WJ
Med Mycol; 2013 Nov; 51(8):811-7. PubMed ID: 23834282
[TBL] [Abstract][Full Text] [Related]
18. Effective plasma concentrations of itraconazole and its active metabolite for the treatment of pulmonary aspergillosis.
Nakamura Y; Matsumoto K; Sato A; Morita K
J Infect Chemother; 2020 Feb; 26(2):170-174. PubMed ID: 31481305
[TBL] [Abstract][Full Text] [Related]
19. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring.
Lestner JM; Roberts SA; Moore CB; Howard SJ; Denning DW; Hope WW
Clin Infect Dis; 2009 Sep; 49(6):928-30. PubMed ID: 19681707
[TBL] [Abstract][Full Text] [Related]
20. Rifamycin treatment of tuberculosis in a patient receiving atenolol: less interaction with rifabutin than with rifampin.
Goldberg SV; Hanson D; Peloquin CA
Clin Infect Dis; 2003 Aug; 37(4):607-8. PubMed ID: 12905149
[No Abstract] [Full Text] [Related]
[Next] [New Search]
